Cargando…

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rau, Alexander, Kocher, Katharina, Rommel, Mirjam, Kühl, Lennart, Albrecht, Maximilian, Gotthard, Hannes, Aschmoneit, Nadine, Noll, Bettina, Olayioye, Monilola A., Kontermann, Roland E., Seifert, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993124/ https://www.ncbi.nlm.nih.gov/pubmed/33752566 http://dx.doi.org/10.1080/19420862.2021.1902034

Ejemplares similares

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

The eIg technology to generate Ig-like bispecific antibodies
por: Kühl, Lennart, et al.
Publicado: (2022)

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)
por: Aschmoneit, Nadine, et al.
Publicado: (2022)

Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
por: Olayioye, Monilola A
Publicado: (2001)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Spatiotemporal Control of Intracellular Membrane Trafficking by Rho GTPases
por: Olayioye, Monilola A., et al.
Publicado: (2019)

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
por: Turini, Marc, et al.
Publicado: (2014)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
por: Malm, Magdalena, et al.
Publicado: (2016)

Spatial Rho regulation: Molecular mechanisms controlling the GAP protein DLC3
por: Hendrick, Janina, et al.
Publicado: (2016)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells
por: Möller, Yvonne, et al.
Publicado: (2014)

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis
por: Leung, Kin-Mei, et al.
Publicado: (2015)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
por: James, N D, et al.
Publicado: (2001)

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION
por: Xu, Ting, et al.
Publicado: (2023)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Proteasomal turnover of the RhoGAP tumor suppressor DLC1 is regulated by HECTD1 and USP7
por: Frey, Yannick, et al.
Publicado: (2022)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

To Dab or Not to Dab: Rising Concerns Regarding the Toxicity of Cannabis Concentrates
por: Alzghari, Saeed K, et al.
Publicado: (2017)

An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer
por: Guo, Xiao-Fang, et al.
Publicado: (2014)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
por: Bass, Tarek Z., et al.
Publicado: (2017)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rst3lsatsjt80nq9o2raqkr0hj